T-group (topology)
10.3.1 TNF-like
Ligands and drugs
1,172
Member domains
494
with ligand contacts (≤ 4 Å)
42.2% of members
424
with DrugDomain annotations
36.2% of members
134
with a DrugBank compound
11.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 10.3.1 belongs to X-group 10 jelly-roll, which binds 8.5 ligand superclasses per 20 proteins, broader than 66% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 42 |
| DB00142 | GLU | Glutamic acid | 3 |
| DB01593 | — | — | 2 |
| DB02843 | G1P | alpha-D-glucose-1-phosphate | 2 |
| DB03570 | 144 | Tris-Hydroxymethyl-Methyl-Ammonium | 2 |
| DB04332 | ETE | 2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol | 2 |
| DB04522 | SEP | Dexfosfoserine | 2 |
| DB14487 | — | — | 2 |
| DB14533 | — | — | 2 |
| DB00480 | — | — | 1 |
| DB00608 | — | Chloroquine | 1 |
| DB00668 | — | Epinephrine | 1 |
| DB00852 | — | — | 1 |
| DB01407 | — | — | 1 |
| DB01411 | — | Pranlukast | 1 |
| DB01427 | — | — | 1 |
| DB02676 | B3P | 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol | 1 |
| DB03740 | NDG | N-acetyl-alpha-D-glucosamine | 1 |
| DB04297 | — | Trichostatin A | 1 |
| DB05412 | — | Talmapimod | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 88 |
| CAmetal | CALCIUM ION | 57 |
| JNI | ~{N}4-(phenylmethyl)-~{N}4-[2-[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]phenyl]pyrimidine-2,4-diamine | 47 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 39 |
| CL | CHLORIDE ION | 38 |
| NAmetal | SODIUM ION | 32 |
| ZNmetal | ZINC ION | 22 |
| Kmetal | POTASSIUM ION | 10 |
| MJO | N-(beta-L-Fucopyranosyl)-biphenyl-3-carboxamide | 10 |
| NImetal | NICKEL (II) ION | 8 |
| BR | BROMIDE ION | 7 |
| A1CBZ | (6R,13R,14S)-1-(difluoromethoxy)-11-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-7H-6,14-methanopyrido[3',2':4,5]imidazo[1,2-b][2,5]benzodiazocin-5(14H)-one | 6 |
| A1CCE | (4S,8aR)-7-{5-[(6R,13R,14S)-5,14-dihydro-7H-6,14-methanopyrido[3',2':4,5]imidazo[1,2-b][2,5]benzodiazocin-11-yl]pyrimidin-2-yl}hexahydroimidazo[1,5-a]pyrazin-3(2H)-one | 6 |
| A7G | 1-{[2-(difluoromethoxy)phenyl]methyl}-2-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1H-benzimidazole | 6 |
| CDmetal | CADMIUM ION | 6 |
| D84 | 5-(1-{[2-(difluoromethoxy)phenyl]methyl}-2-{[3-(2-oxopyrrolidin-1-yl)phenoxy]methyl}-1H-benzimidazol-6-yl)pyridin-2(1H)-one | 6 |
| GLU | GLUTAMIC ACID | 6 |
| UTJ | [4-(isoquinolin-8-yl)phenyl]acetonitrile | 6 |
| UTM | 8-[4-(2-{5-[(4-methylpiperazin-1-yl)methyl]-2-(1H-pyrrolo[3,2-c]pyridin-3-yl)phenoxy}ethyl)phenyl]isoquinoline | 6 |
| UTS | 1-benzyl-1H-benzimidazole | 6 |